Latest News

GattaCo and iAssay Join Forces in COVID-19 Fight

Murrieta / San Diego— 11/10/2020Today GattaCo and iAssay announced that they have signed a Memorandum of Understanding (MOU), enabling engineers and scientists to work together to integrate and optimize their products in an effort to provide enhanced rapid serology testing, including COVID-19 antibody testing and electronic test result transmission to federal and state agencies via the cloud at the point of care.

“Helping to alleviate the COVID-19 testing bottleneck with improved test accuracy, eliminating the need for centrifugation of blood samples and reducing clinical lab restrictions will improve patient care and at the same time, provide public health agencies and other vested parties relevant data to support informed decision making and improved management of the COVID-19 crisis,” said Dr. Michael McNeely, President and CEO of GattaCo.

Combining Power

GattaCo developed and patented rapid and automatic plasma separation tools, called the A-PON™ and pediatric-focused mini-PON™ Kits. The PON Kits (PON referring to plasma at the point of need) separate antibody-rich plasma from whole blood collected from a finger-stick without the need for a centrifuge or venous blood-draw. The plasma generated by the PON Kits can transform a normally Yes or No antibody test to a semi-quantitative test and enable more sensitive quantitative detection by the iAssay CyberReader™ device, reducing false positives and negatives.

iAssay’s CyberReader™ automatically quantifies and analyzes COVID-19 test strips, then transmits the test results electronically to doctors, hospitals, and state and federal agencies.  The Department of Health and Human Services (HHS) now requires that both positive and negative COVID-19 test results be reported to them or risk being fined $1,000 for the first violation, and $500 per day for ongoing violations.

An Elegant and Complimentary Solution

When used as directed, PON derived plasma can be obtained in under three minutes, in any setting, including at a doctor’s office, at home, at screening centers, or anywhere finger-stick blood can be collected. The A-PON and mini-PON Kits require no power, support equipment or skill on the part of the user, eliminating the need for the phlebotomist, lab tech and centrifuge infrastructure that is otherwise required to obtain plasma. The battery-powered iAssay CyberReader™ provides a quick and portable method for analyzing strips incubated with PON produced plasma and storing test results in the Cloud.

“It’s a natural fit for both companies,” said Lonnie Adelman, CEO & Founder at iAssay. “iAssay provides a sensitive and accurate Reader device and Cloud connectivity, and GattaCo provides the microfluidics that optimize the strip chemical reactions.  Together, we are working on improving the full system performance by using our combined strengths in engineering and biotechnological medical device design,” Adelman added.

US manufacturing and distribution is set to begin as soon as all governmental requirements are met.   

For more information on  iAssay:

Diana Short

Executive Administration

For more information on GattaCo:

Mahmoud Zubaidi

Chief Science Officer

CyberReader Model 2030
A-PON Automatic Plasma Separation Tool